US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Serina Therapeutics, Inc.

5.85

-0.2400-3.94%

Volume:10.89K

Turnover:62.37K

Market Cap:58.10M

PE:-3.86

High:6.03

Open:6.03

Low:5.44

Close:6.09

Loading ...

Overview Company News Filings

Serina Therapeutics receives funding to advance SER-252 into clinical trial

Serina Therapeutics Secures $5 Million for SER-252 Trials

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

THOMSON REUTERS

Serina Therapeutics Inc - Funding to Advance Ser-252 Into Phase 1 Trial in H2 2025

THOMSON REUTERS

Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics

Serina Therapeutics Sells UniverXome Subsidiary

Serina Therapeutics sells UniverXome subsidiary

Serina Therapeutics Sells UniverXome Unit

MT Newswires Live

Serina Therapeutics Announces Sale of Univerxome Subsidiary

THOMSON REUTERS

Serina Therapeutics Inc - Transaction Eliminates $11.2 Million in Debt

THOMSON REUTERS

BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of Directors

Serina Therapeutics Welcomes Karen J. Wilson to Its Board of Directors

THOMSON REUTERS

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

MT Newswires Live

Seres announces new translational biomarker results from SER-155 Phase 1b study

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Serina Therapeutics Announces SER-252 for Parkinson’s Trials

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics granted Breakthrough Therapy designation for SER-155

BRIEF-FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SER/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SER","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","market":"US","secType":"STK","nameCN":"Serina Therapeutics, Inc.","latestPrice":5.85,"timestamp":1745611200000,"preClose":6.09,"halted":0,"volume":10885,"delay":0,"floatShares":2757765,"shares":9932215,"eps":-1.513928,"marketStatus":"Pre-Mkt","change":-0.24,"latestTime":"04-28 05:31:03 EDT","open":6.025,"high":6.025,"low":5.44,"amount":62365.5125,"amplitude":0.096059,"askPrice":6.67,"askSize":100,"bidPrice":2.34,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.513928,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745847000000},"marketStatusCode":1,"adr":0,"exchange":"AMEX","adjPreClose":5.85,"volumeRatio":0.6170075248639237},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SER\",,,,,undefined,":{"symbol":"SER","floatShares":2757765,"roa":"-124.04%","roe":"-485.36%","lyrEps":-1.513928,"volumeRatio":0.6170075248639237,"shares":9932215,"dividePrice":0,"high":6.025,"amplitude":0.096059,"preClose":6.09,"low":5.44,"week52Low":3.81,"pbRate":"90.65","psRate":"1037.56","week52High":14.57,"institutionHeld":0,"latestPrice":5.85,"committee":0.333333,"eps":-1.513928,"divideRate":0,"volume":10885,"delay":0,"ttmEps":-1.513928,"open":6.025,"prevYearClose":5.01,"prevWeekClose":5.85,"prevMonthClose":5.67,"prevQuarterClose":5.67,"fiveDayClose":5.25,"twentyDayClose":4.75,"sixtyDayClose":4.63},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SER\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2508175659","title":"Serina Therapeutics receives funding to advance SER-252 into clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175659?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:45","pubTimestamp":1738619117,"startTime":"0","endTime":"0","summary":"Serina Therapeutics (SER) announced the closing of the second $5M tranche of its previously announced $10M equity financing with strategic sharehol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-receives-funding-to-advance-ser-252-into-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-receives-funding-to-advance-ser-252-into-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2508175507","title":"Serina Therapeutics Secures $5 Million for SER-252 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175507","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175507?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:35","pubTimestamp":1738618513,"startTime":"0","endTime":"0","summary":"Serina Therapeutics ( ($SER) ) has provided an update. On February 3, 2025, Serina Therapeutics announced the completion of a second $5 million tra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-secures-5-million-for-ser-252-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-secures-5-million-for-ser-252-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2508971173","title":"Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2508971173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508971173?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:30","pubTimestamp":1738618200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA8SDJR3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2508173187","title":"Serina Therapeutics Inc - Funding to Advance Ser-252 Into Phase 1 Trial in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173187?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:30","pubTimestamp":1738618200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA8SDJR3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2503601701","title":"Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503601701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503601701?lang=en_us&edition=fundamental","pubTime":"2025-01-16 07:45","pubTimestamp":1736984700,"startTime":"0","endTime":"0","summary":"Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing it to enter 2025 with a debt-free balance sheet. Chief Executive Steve Ledger added that the deal will allow Serina to continue advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. Shares jump 21%, to $5.84, in postmarket trading.Powell Max said it has commenced activities to pursue acquisitions as part of its business strategy. The company is evaluating other financial communications service providers, planning to acquire companies generating $1.5 million to $5 million in gross annual revenue. It intends to retain most of the management teams of any acquired companies. Shares surge 84%, to $2.54, in after-hours trading.Silexion Therapeutics released what the company called promising preclinical data for its treatment of pancreatic cancer. The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","US12M.BOND","LENZ","US7Y.BOND","US30Y.BOND","US3Y.BOND","US6M.BOND","PMAX","BK4078","GPRO","US10Y.BOND","SER","BK4096","BK4139","US5Y.BOND","US2Y.BOND","BK4588","SLXN","BK4112"],"gpt_icon":1},{"id":"2503928670","title":"Serina Therapeutics Sells UniverXome Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503928670","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503928670?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:33","pubTimestamp":1736976780,"startTime":"0","endTime":"0","summary":"Serina Therapeutics on Wednesday said it has sold its UniverXome subsidiary in a deal which was finalized on Dec. 23.The biotechnology company said on Wednesday that the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing the company to enter 2025 with a debt-free balance sheet.Chief Executive Officer Steve Ledger said the deal allows Serina to continue its focus on advancing SER-252, its lead candidate for advanced Parkinson's disease, into clinical development. The deal also allows the company to further explore the potential of its POZ platform, a technology designed to provide greater control in drug loading and the rate of release of drugs delivered via subcutaneous injection, Ledger said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SER","BK4139"],"gpt_icon":0},{"id":"2503670490","title":"Serina Therapeutics sells UniverXome subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503670490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503670490?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:25","pubTimestamp":1736976334,"startTime":"0","endTime":"0","summary":"Serina Therapeutics (SER) announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-sells-univerxome-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/serina-therapeutics-sells-univerxome-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","SER"],"gpt_icon":0},{"id":"2503770966","title":"Serina Therapeutics Sells UniverXome Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2503770966","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503770966?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:20","pubTimestamp":1736976041,"startTime":"0","endTime":"0","summary":"Serina Therapeutics  said Wednesday it sold its UniverXome subsidiary.The deal, which was finalized on Dec. 23, cut $11.2 million in associated subsidiary-level debt, Serina said, adding it now has a debt-free balance sheet.The unit was set up before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold the legacy assets of the predecessor company, Serina said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SER","LENZ","SER.AU","BK4139","BK7095"],"gpt_icon":0},{"id":"2503773736","title":"Serina Therapeutics Announces Sale of Univerxome Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2503773736","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503773736?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUA8BPQTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2503677378","title":"Serina Therapeutics Inc - Transaction Eliminates $11.2 Million in Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2503677378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503677378?lang=en_us&edition=fundamental","pubTime":"2025-01-16 05:05","pubTimestamp":1736975100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUA8BPQTD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2503768012","title":"BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2503768012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503768012?lang=en_us&edition=fundamental","pubTime":"2025-01-15 06:26","pubTimestamp":1736893600,"startTime":"0","endTime":"0","summary":"BRIEF-Serina Therapeutics Welcomes Karen J. Wilson To Its Board Of DirectorsJan 14 (Reuters) - Serina Therapeutics SER.A:SERINA THERAPEUTICS WELCOMES KAREN J. WILSON TO ITS BOARD OF DIRECTORSSource text: ID:nGNX3GJmS1Further company coverage: SER.A ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA5KCWH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2503680488","title":"Serina Therapeutics Welcomes Karen J. Wilson to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2503680488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503680488?lang=en_us&edition=fundamental","pubTime":"2025-01-15 06:25","pubTimestamp":1736893500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA5KCWH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SER"],"gpt_icon":0},{"id":"2502047235","title":"Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended","url":"https://stock-news.laohu8.com/highlight/detail?id=2502047235","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502047235?lang=en_us&edition=fundamental","pubTime":"2025-01-10 01:33","pubTimestamp":1736443981,"startTime":"0","endTime":"0","summary":"Seres Therapeutics  said results from a phase 1b trial of SER-155 in people undergoing allogenic stem cell transplantation showed a \"positive impact on biomarkers of systemic inflammation and immune homeostasis\" compared with placebo.The results back previous data showing that SER-155 \"was associated with a significant reduction in bloodstream infections,\" the company said Thursday in a statement.SER-155 is a live biotherapeutic designed to prevent infections in people undergoing allogenic stem cell transplantation to treat blood cancers, Seres said.The company also said its cash runway was extended into Q1 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MCRB","SER","BK4139"],"gpt_icon":0},{"id":"2502016368","title":"Seres announces new translational biomarker results from SER-155 Phase 1b study","url":"https://stock-news.laohu8.com/highlight/detail?id=2502016368","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502016368?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:15","pubTimestamp":1736424932,"startTime":"0","endTime":"0","summary":"Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seres-announces-new-translational-biomarker-results-from-ser-155-phase-1b-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seres-announces-new-translational-biomarker-results-from-ser-155-phase-1b-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SER","BK4139","MCRB"],"gpt_icon":0},{"id":"2502659015","title":"Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2502659015","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502659015?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":"New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased syst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3006947/0/en/Seres-Therapeutics-Announces-New-Translational-Biomarker-Results-from-SER-155-Phase-1b-Clinical-Study-and-Provides-Corporate-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4006","SER","MCRB","BK4585","BK4588","AMR"],"gpt_icon":0},{"id":"2501239260","title":"Serina Therapeutics Announces SER-252 for Parkinson’s Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2501239260","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501239260?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:31","pubTimestamp":1736199090,"startTime":"0","endTime":"0","summary":"The latest update is out from Serina Therapeutics ( ($SER) ). Serina Therapeutics has announced the development of its lead program, SER-252, which...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-announces-ser-252-for-parkinsons-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/serina-therapeutics-announces-ser-252-for-parkinsons-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SER","BK4139"],"gpt_icon":0},{"id":"2491660080","title":"Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660080?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:30","pubTimestamp":1734352230,"startTime":"0","endTime":"0","summary":"Seres Therapeutics (MCRB) announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-to-highlight-plans-for-ser-155-at-jpmorgan-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-to-highlight-plans-for-ser-155-at-jpmorgan-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1032466523.USD","IE00BDRTCR15.USD","LU2237443622.USD","SER","BK4533","LU1074936037.SGD","LU1548497426.USD","LU1244550494.USD","LU1670627923.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU2023250504.SGD","LU0310799852.SGD","LU1267930490.SGD","IE00BKDWB100.SGD","LU1363072403.SGD","LU2237443465.HKD","LU1989772923.USD","SG9999002232.USD","IE00BJTD4N35.SGD","LU1496350502.SGD","MCRB","LU1119994496.HKD","LU0787776722.HKD","LU1894683264.USD","BK4566","LU1670628061.USD","LU0149725797.USD","LU1720051017.SGD","LU1917777945.USD","LU2271345857.HKD","LU2242649171.HKD","IE00BDCRKT87.USD","IE00BLSP4239.USD","LU2264538146.SGD","BK4581","LU0211326755.USD","LU1914381329.SGD","LU1084165304.USD","LU0238689110.USD","LU1064131342.USD","LU1988902786.USD","LU1496350171.SGD","LU0098860793.USD","LU2552382132.HKD","IE00B775SV38.USD","LU0203347892.USD","LU0158827781.USD","LU2023250843.SGD","IE00BWXC8680.SGD"],"gpt_icon":0},{"id":"2490729258","title":"Seres Therapeutics granted Breakthrough Therapy designation for SER-155","url":"https://stock-news.laohu8.com/highlight/detail?id=2490729258","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490729258?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:25","pubTimestamp":1733747107,"startTime":"0","endTime":"0","summary":"Seres Therapeutics (MCRB) announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to SER-155, the Company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-granted-breakthrough-therapy-designation-for-ser-155?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/seres-therapeutics-granted-breakthrough-therapy-designation-for-ser-155?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SER","MCRB","BK4139"],"gpt_icon":0},{"id":"2490072656","title":"BRIEF-FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155","url":"https://stock-news.laohu8.com/highlight/detail?id=2490072656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490072656?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:13","pubTimestamp":1733746385,"startTime":"0","endTime":"0","summary":"Dec 9  - Seres Therapeutics Inc   :   * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO SERES THERAPEUTICS’ SER-155 FOR REDUCTION OF BLOODSTREAM INFECTIONS IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT    * SERES THERAPEUTICS INC - FDA MEETING ON NEXT STUDY OF SER-155 EXPECTED IN Q1 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SER","MCRB","BK4139"],"gpt_icon":0},{"id":"2490726830","title":"FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490726830","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490726830?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:00","pubTimestamp":1733745600,"startTime":"0","endTime":"0","summary":"Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meetin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993621/0/en/FDA-Grants-Breakthrough-Therapy-Designation-to-Seres-Therapeutics-SER-155-for-Reduction-of-Bloodstream-Infections-in-Adults-Undergoing-Allogeneic-Hematopoietic-Stem-Cell-Transplant.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","AMR","BK4006","HSCT","BK4588","MCRB","SER","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SER\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-24","symbol":"SER","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2024-11-12","symbol":"SER","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2024-08-09","symbol":"SER","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":0.51},{"market":"US","date":"2024-05-14","symbol":"SER","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-3.38},{"market":"US","date":"2024-03-22","symbol":"SER","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711080000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SER\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SER\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1741665600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SER\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SER","date":"2025-04-25","current":-5.429242,"percent":0.748,"low":-19.318735,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"high":37.356482,"avg":-4.004103,"sd":10.096115,"marketCap":60487189},"quantilePoints":[{"date":"2024-04-05","current":29.141387,"twenty":30.584579,"median":32.083279,"eighty":33.732959,"marketCap":105541506},{"date":"2024-04-12","current":17.770243,"twenty":17.783016,"median":23.543628,"eighty":32.232039,"marketCap":93646584},{"date":"2024-04-19","current":17.456349,"twenty":17.731924,"median":17.945869,"eighty":31.172957,"marketCap":91992413},{"date":"2024-04-26","current":14.673941,"twenty":16.787882,"median":17.778226,"eighty":29.502185,"marketCap":77329529},{"date":"2024-05-03","current":14.209648,"twenty":14.673941,"median":17.57865,"eighty":21.283439,"marketCap":74882770},{"date":"2024-05-10","current":14.050147,"twenty":14.209648,"median":17.078432,"eighty":18.800885,"marketCap":74042223},{"date":"2024-05-17","current":12.820759,"twenty":14.187327,"median":15.966076,"eighty":18.090969,"marketCap":67563528},{"date":"2024-05-24","current":15.167772,"twenty":14.187327,"median":15.718602,"eighty":17.818141,"marketCap":79931945},{"date":"2024-05-31","current":-13.721878,"twenty":13.545619,"median":15.079879,"eighty":17.786209,"marketCap":79931945},{"date":"2024-06-07","current":-14.08298,"twenty":12.926135,"median":14.744671,"eighty":17.776629,"marketCap":82035417},{"date":"2024-06-14","current":-14.564515,"twenty":-13.557216,"median":14.673941,"eighty":17.770243,"marketCap":84840426},{"date":"2024-06-21","current":-15.922863,"twenty":-13.825876,"median":14.209648,"eighty":17.731924,"marketCap":92753004},{"date":"2024-06-28","current":-12.919404,"twenty":-13.944317,"median":14.209648,"eighty":17.655287,"marketCap":75257414},{"date":"2024-07-05","current":-11.364849,"twenty":-13.990538,"median":14.209648,"eighty":17.52973,"marketCap":66201907},{"date":"2024-07-12","current":-11.153551,"twenty":-13.799876,"median":13.810656,"eighty":17.339222,"marketCap":64971062},{"date":"2024-07-15","current":-13.477836,"twenty":-13.773877,"median":13.571165,"eighty":17.280659,"marketCap":78510363},{"date":"2024-08-02","current":-12.964682,"twenty":-13.747877,"median":13.539233,"eighty":17.222095,"marketCap":75521166},{"date":"2024-08-09","current":-11.364095,"twenty":-13.723872,"median":13.251843,"eighty":17.027373,"marketCap":66197511},{"date":"2024-08-16","current":-8.441425,"twenty":-13.721878,"median":2.384851,"eighty":16.171527,"marketCap":59150297},{"date":"2024-08-23","current":-10.330099,"twenty":-13.617881,"median":-8.582039,"eighty":15.966076,"marketCap":72384510},{"date":"2024-08-30","current":-10.13985,"twenty":-13.52255,"median":-9.00413,"eighty":15.966076,"marketCap":71051408},{"date":"2024-09-06","current":-10.104487,"twenty":-13.488788,"median":-9.975078,"eighty":15.85112,"marketCap":70803616},{"date":"2024-09-13","current":-7.831133,"twenty":-13.268937,"median":-9.379361,"eighty":15.707426,"marketCap":54873890},{"date":"2024-09-20","current":-7.554188,"twenty":-13.112179,"median":-8.839249,"eighty":15.365752,"marketCap":52933298},{"date":"2024-09-27","current":-9.43006,"twenty":-13.019016,"median":-9.049816,"eighty":15.0623,"marketCap":66077809},{"date":"2024-10-04","current":-8.251303,"twenty":-12.937515,"median":-8.845695,"eighty":14.905865,"marketCap":57818083},{"date":"2024-10-11","current":-8.580848,"twenty":-12.554189,"median":-8.732946,"eighty":14.786183,"marketCap":60127254},{"date":"2024-10-18","current":-9.769745,"twenty":-12.214089,"median":-8.764633,"eighty":14.702233,"marketCap":68458031},{"date":"2024-10-25","current":-8.872369,"twenty":-11.941393,"median":-8.872369,"eighty":14.673941,"marketCap":62169982},{"date":"2024-10-31","current":-8.568173,"twenty":-11.747964,"median":-8.847019,"eighty":14.628789,"marketCap":60038439},{"date":"2024-11-08","current":-5.742165,"twenty":-11.5456,"median":-8.764633,"eighty":14.420496,"marketCap":40236191},{"date":"2024-11-15","current":-6.048407,"twenty":-11.364849,"median":-8.720054,"eighty":14.209648,"marketCap":44459880},{"date":"2024-11-22","current":-5.928673,"twenty":-11.364547,"median":-8.695365,"eighty":14.209648,"marketCap":43570682},{"date":"2024-11-29","current":-6.352149,"twenty":-11.321986,"median":-8.600455,"eighty":14.209648,"marketCap":46682874},{"date":"2024-12-06","current":-7.456945,"twenty":-11.110513,"median":-8.568173,"eighty":14.187327,"marketCap":54802179},{"date":"2024-12-13","current":-6.006451,"twenty":-10.914992,"median":-8.561836,"eighty":14.088465,"marketCap":44142287},{"date":"2024-12-20","current":-7.07266,"twenty":-10.789111,"median":-8.479449,"eighty":13.954351,"marketCap":51978012},{"date":"2024-12-27","current":-6.747673,"twenty":-10.659517,"median":-8.390726,"eighty":13.571165,"marketCap":49589633},{"date":"2025-01-03","current":-6.517639,"twenty":-10.562175,"median":-8.162579,"eighty":13.520073,"marketCap":47899077},{"date":"2025-01-10","current":-5.904214,"twenty":-10.499761,"median":-8.051056,"eighty":13.363605,"marketCap":43390929},{"date":"2025-01-17","current":-6.07035,"twenty":-10.463782,"median":-7.83254,"eighty":13.258229,"marketCap":44611886},{"date":"2025-01-24","current":-6.006451,"twenty":-10.451708,"median":-7.712623,"eighty":13.14966,"marketCap":44142287},{"date":"2025-01-31","current":-5.878654,"twenty":-10.421318,"median":-7.617562,"eighty":12.926135,"marketCap":43203089},{"date":"2025-02-07","current":-5.878654,"twenty":-10.364245,"median":-7.402632,"eighty":5.571028,"marketCap":43203089},{"date":"2025-02-14","current":-5.955332,"twenty":-10.299629,"median":-7.207741,"eighty":-5.38422,"marketCap":43766608},{"date":"2025-02-21","current":-6.249265,"twenty":-10.231108,"median":-7.041606,"eighty":-5.510713,"marketCap":45926762},{"date":"2025-02-28","current":-6.380056,"twenty":-10.13985,"median":-6.713492,"eighty":-5.574659,"marketCap":46887966},{"date":"2025-03-07","current":-6.326216,"twenty":-10.13478,"median":-6.696682,"eighty":-5.743169,"marketCap":46492287},{"date":"2025-03-14","current":-5.532074,"twenty":-10.112497,"median":-6.684888,"eighty":-5.743169,"marketCap":40656021},{"date":"2025-03-21","current":-6.110856,"twenty":-10.104487,"median":-6.616553,"eighty":-5.743169,"marketCap":44909571},{"date":"2025-03-28","current":-4.234631,"twenty":-10.098885,"median":-6.511249,"eighty":-5.532216,"marketCap":47178021},{"date":"2025-04-04","current":-4.894342,"twenty":-10.073941,"median":-6.460817,"eighty":-4.926436,"marketCap":54527860},{"date":"2025-04-11","current":-4.279206,"twenty":-10.051126,"median":-6.404799,"eighty":-4.716041,"marketCap":47674632},{"date":"2025-04-17","current":-4.680381,"twenty":-10.000427,"median":-6.391338,"eighty":-4.680381,"marketCap":52144128},{"date":"2025-04-25","current":-5.429242,"twenty":-9.949728,"median":-6.352149,"eighty":-4.680381,"marketCap":60487189}],"updateTime":1745832663071}}}